Protalix BioTherapeutics EV/EBIT PLX

Enterprise value divided by operating profit over the last twelve months, one-off items taken out, since 2020.

Today, Oct 23, 2026: 7.5×
6-year median: 15.7×
Against its 6-year history: 23rd; percentile: 0 is its lowest day, 100 its highest
6-year range: 5.9× to 114×
Peer median: 14.2×

Protalix BioTherapeutics' EV/EBIT is 7.5× as of Oct 23, 2026.

That is below its 6-year median of 15.7×, lower than on 77% of days in the last 6 years.

Over that time it ranged from 5.9× in May 2026 to 114× in Apr 2021.

The median for 10 healthcare stocks of a similar size is 14.2×.

EV/EBIT over time

Open the interactive chart, with overlays and comparisons

Year by year

Year	End of year	Low	High
2026 so far	7.5×	5.9×	35.3×
2025	19.5×	10.9×	52.3×
2024	6.7×	6.2×	8.4×
2023	8.5×	6.1×	9.7×
2022	n/m a value too high to mean anything
2021	60.4×	60.4×	114×
2020	69.2×	44.1×	74.5×

Against its peers

Companies in Healthcare nearest Protalix BioTherapeutics' size, closest first, today.

Company	EV/EBIT
PLXProtalix BioTherapeutics	7.5×
PDEXPro DEX	16.0×
NATRNatures Sunshine Products	5.2×
ELMDElectromed	14.4×
UTMDUtah Medical Products	6.0×
INFUInfuSystem	22.4×
VMDViemed Healthcare	16.3×
EMBCEmbecta	6.7×
KEQUKewaunee Scientific	7.2×
ICCCImmucell	14.2×
ARVNArvinas	n/m
Peer median	14.2×

Where Protalix BioTherapeutics ranks

What the EV/EBIT tells you

What the whole business costs against its operating profit. Enterprise value is the market value plus borrowings and minority interests, less cash. EBIT is operating profit before interest and tax, with one-offs taken out. Unlike PE it is not moved by how a company is financed.

Leases are left out of debt for every company. Banks earn on their balance sheet, so EV/EBIT does not describe them.

More on Protalix BioTherapeutics

Valuation data, not investment advice. Prices as of Oct 23, 2026. Reported figures come from the company's filings with the SEC.